Table 1.
Response and time to progression in randomized trials comparing aromatase inhibitors and tamoxifen as neoadjuvant therapy or in advanced breast cancer
| Reference | Agent administered | Number of subjects | Response(%) | Clinical benefit(%) | Time to progression(months) |
| [9] | Letrozole | 453 | 30 | 49 | 9.4 |
| Tamoxifen | 454 | 20 | 38 | 6.0 | |
| [13] | Letrozole | 154 | 55 | - | - |
| Tamoxifen | 170 | 36 | - | - | |
| [11] | Anastrozole | 171 | 21 | 59 | 11.1 |
| Tamoxifen | 182 | 17 | 46 | 5.6 | |
| [19] | Anastrozole | 340 | 33 | 56 | 8.2 |
| Tamoxifen | 328 | 33 | 56 | 8.3 | |
| [11] | Anastrozole | 121 | 43 | 83 | - |
| Tamoxifen | 117 | 31 | 56 | - | |
| [10] | Exemestane | 61 | 41 | 57 | - |
| Tamoxifen | 59 | 17 | 42 | - |